Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | AKT1 | P31749 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | CDC25A | P30304 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.58 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | PRKCG | P05129 | 2/20 | 0.50 |
| ▸ | PRKCB | P05771 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.50 |
| ▸ | PRKCH | P24723 | 2/20 | 0.50 |
| ▸ | PRKCI | P41743 | 2/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905581 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL2693659 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL14447829 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL14447816 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL62054 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL7188423 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL14447974 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL2695075 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL60426 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL5707895 | 1.00 | LMNA (0.70) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119454909-B | Formulation composition of glucagon-like peptide-1 receptor agonist for nasal mucosa administration, preparation method, application and nasal applicator | 上海世领制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119454909-A | Formulation composition of glucagon-like peptide-1 receptor agonist for nasal mucosa administration, preparation method, application and nasal applicator | 上海世领制药有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119451386-A | Hole transport layer, perovskite solar cell and preparation method | 天合光能股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3586142-B1 | DETECTION OF MEMBRANE PROTEINS | UNIV OXFORD INNOVATION LTD (GB) | 2024-12-25 | — | — | EP | claimed |
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2023-03-30 | — | — | US | claimed |
| US-11413297-B2 | Therapies for treating and preventing chronic rhinosinusitis | AVANTI POLAR LIPIDS, LLC (US) | 2022-08-16 | — | — | US | claimed |
| US-10955421-B2 | Detection of membrane proteins | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-03-23 | — | — | US | claimed |
| WO-2021028696-A1 | AMOEBICIDAL COMPOSITIONS FOR CONTACT LENS SOLUTIONS | UNIVERSITY OF THE WEST OF SCOTLAND (GB) | 2021-02-18 | — | — | WO | claimed |
| US-20200306274-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | AVANTI POLAR LIPIDS, LLC | 2020-10-01 | — | — | US | claimed |
| US-20200240997-A1 | DETECTION OF MEMBRANE PROTEINS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-07-30 | — | — | US | claimed |
| EP-3684180-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | The Scripps Research Institute (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2019060761-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-03-28 | — | — | WO | claimed |
| WO-2018154318-A1 | DETECTION OF MEMBRANE PROTEINS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-08-30 | — | — | WO | claimed |
| US-9606126-B2 | Compositions and methods for membrane protein detergent stability screen | UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) | 2017-03-28 | — | — | US | claimed |
| US-8703179-B2 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120315459-A1 | CARBON NANOTUBE SHEET AND PROCESS FOR PRODUCTION THEREOF | TAIYO NIPPON SANSO CORPORATION (JP) | 2012-12-13 | — | — | US | claimed |
| US-20090203641-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | ACADEMIA SINICA (TW) | 2009-08-13 | — | — | US | claimed |
| WO-2007133261-A1 | MUCOSAL FORMULATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070264206-A1 | Mucosal formulation | KIMBERLY-CLARK WORLDWIDE, INC. | 2007-11-15 | — | — | US | claimed |
| WO-2005007895-A1 | METHODS AND KITS FOR OBTAINING NUCLEIC ACID FROM BIOLOGICAL SAMPLES | APPLERA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203641-A1 | ANTIBIOTIC COMPOSITIONS AND RELATED SCREENING METHODS | PGLS, MGAM, PTMA | LMNA 811/4885AKT1 1532/4885ESR1 2911/4885 |
| US-20200306274-A1 | NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS | FPR1, CYSLTR1, LPAR5 | LMNA 4066/4885AKT1 1080/4885ESR1 4540/4885 |
| US-20200240997-A1 | DETECTION OF MEMBRANE PROTEINS | CETP, VAPA, PCTP | LMNA 1166/4885AKT1 3039/4885ESR1 3145/4885 |
| US-11413297-B2 | Therapies for treating and preventing chronic rhinosinusitis | FPR1, CFTR, FPR3 | LMNA 3383/4885AKT1 1787/4885ESR1 4444/4885 |
| US-20070264206-A1 | Mucosal formulation | MUC1, CHMP4B, VMA21 | LMNA 2111/4885AKT1 1224/4885ESR1 1954/4885 |
| US-10955421-B2 | Detection of membrane proteins | CETP, VAPA, PCTP | LMNA 1166/4885AKT1 3039/4885ESR1 3145/4885 |
| US-20230102836-A1 | Amoebicidal Compositions for Contact Lens Solutions | APH1B, PHOSPHO1, UACA | LMNA 635/4885AKT1 1194/4885ESR1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.